Aravive (NASDAQ:ARAV) Full Year 2022 Results
Key Financial Results
- Revenue: US$9.14m (up 23% from FY 2021).
- Net loss: US$76.3m (loss widened by 95% from FY 2021).
- US$2.10 loss per share (further deteriorated from US$1.95 loss in FY 2021).
ARAV Products In Clinical Trials
- Phase I: 1.
- Phase II: 3.
- Phase III: 1.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Aravive Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 9.8%. Earnings per share (EPS) missed analyst estimates by 16%.
Looking ahead, revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are up 14% from a week ago.
Risk Analysis
You should learn about the 4 warning signs we've spotted with Aravive (including 2 which are a bit concerning).
Valuation is complex, but we're here to simplify it.
Discover if Aravive might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.